All In Biotech

Drug Trial Radar · NCT07261241

NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab

NANT 2021-02: A Randomized Phase 2 Study of 131I-MIBG With Vorinostat VS. 131I-MIBG With Dinutuximab vs. 131I-MIBG With Dinutuximab and Vorinostat for Relapsed or Refractory Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 118 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

118

Planned (sponsor's estimate)

Start

Dec 31, 2026

Primary completion

Dec 31, 2030

Study completion Dec 31, 2031

Sponsor

Lead sponsor
New Approaches to Neuroblastoma Therapy ConsortiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United Therapeutics; Jubilant DraxImage Inc.
First posted
Dec 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients will then be randomized at study entry to one of three treatment arms. Patients on Arm A will receive a single treatment course with 131I-MIBG with vorinostat. Patients on Arm B will receive a single treatment course with 131I-MIBG and dinutuximab. Patients on Arm C will receive a single treatment course with 131I-MIBG with dinutuximab + vorinostat. After this course of treatment, we will check to see your response and then check to see how you are doing over time. All patients may choose to proceed to a second course of the same treatment if they and their physician feel healthy enough to do so. Approximately 118 patients will be receiving therapy on this trial.

Conditions

  • Neuroblastoma

Interventions

  • Radiation: 131I-MIBGDrug

    Patients will receive 131I-MIBG 18 mCi/kg (maximum dose 1200 mCi) on Day 1

  • DinutuximabDrug

    Dinutuximab 17.5 mg/m2/day is given intravenously on Days 8-11 and 29-32 of therapy

  • VorinostatDrug

    Vorinostat will be given on days 0-13 at a dose of 180 mg/m2/dose (maximum dose 400 mg).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Tumor Response After One Course of TherapyTime frame: 43-57 days from study day 1

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital Los Angeles

    Los Angeles, California

  • UCSF Helen Diller Family Comprehensive Cancer Center

    San Francisco, California

  • Children Hospital of Colorado

    Aurora, Colorado

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Children's Memorial Hospital - Chicago

    Chicago, Illinois

  • Childrens Hospital Boston, Dana-Farber Cancer Institute.

    Boston, Massachusetts

  • C.S Mott Children's Hospital

    Ann Arbor, Michigan

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • University of Texas Southwestern

    Dalls, Texas

  • Cook Children's Medical Center - Fort Worth

    Fort Worth, Texas

  • Children's Hospital and Regional Medical Center - Seattle

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.